DermTech (DMTK) Announces Contract With North Carolina Blues Plan for the Foundational Assay of Its DermTech Melanoma Test
DermTech, Inc. (NASDAQ:) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a Blues plan in North Carolina. The contract, which is in addition to a favorable coverage policy that became effective March 15, 2023, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the more than 3.8 million members of this plan. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99 percent negative predictive value (NPV).
“We are eager to strengthen our connection with this major payer in North Carolina and further reduce barriers to access with our test now available as an in-network benefit,” said Chris Murphy, senior director of payor access, DermTech. “The DMT test results are clinically meaningful and actionable, improve patient care and reduce healthcare costs. After reviewing our portfolio of clinical and health economic data, payers are recognizing the value of our test and resulting benefits to their membership, network providers and health plans.”
DermTech’s total covered lives in the U.S. are approximately 126 million, which includes 68 million for Medicare/Medicare Advantage and 58 million for commercial and governmental payers.
[ad_2]
Source link